Characteristic	Hamilton 2003	Sarnblad 2003
Intervention 1 (I1) / control 1 (C1)	I1: oral metformin and s.c. insulin (randomised[n]=15) C1: placebo and s.c. insulin (randomised[n]=15)	I1: oral metformin and s.c. insulin (randomised[n]=16) C1: placebo and s.c. insulin (randomised[n]=14)
[n] of participants who died	N	Not reported
[n] adverse events (I1/ I2 / C1 / total)	I:11 C: 7 Total: 18	I: 3 C: 6 Total: 9
[%] adverse events	I: 73% C: 47%	I: 19% C: 43%
[n] serious adverse events	I: 2 C: 2	N
[%] serious adverse events	I: 13% C: 13%	N
[n] drop‐outs due to adverse events	I1: 2 C1: 1 Total:3	I: 1 C: 0
[%] drop‐outs due to adverse events	I1: 13% C1: 7% Total:20%	I: 6% C: 0%
[n] hypoglycaemic episodes	I:2 C:1 mild hypoglycemia after 3 months: I: Mean 1.75 (0.8) events/patient/week C: Mean 0.9 (0.4) events/patient/week	N
[%] hypoglycaemic episodes	I: 13% C: 7%	N
[n] severe hypoglycaemic episodes	I: 2 C:1	N
[%] severe hypoglycaemic episodes	I: 13% C: 7%	N
[n] nocturnal hypoglycaemic episodes	?	N
[%] nocturnal hypoglycaemic episodes	?	N
[n] with symptoms	I: 2 C: 1	N
[%] with symptoms	I: 13% C: 7%	N
[n] with GIT upset	I: 9 C: 5	I: 3 C: 6 Total: 9
[%] with GIT upset	I: 60% C: 33%	I: 19% C: 43%
[%] with severe GIT upset	I:13% C:0%	N
[n] with lactic acidosis	N	N
[%] with lactic acidosis	N	N
[%] with severe lactic acidosis	N	N
Footnotes: Y = yes; N = no; ? = unclear I = intervention; C = control